Cargando…

New targets for resistant prostate cancer

Detalles Bibliográficos
Autores principales:	Thompson, Timothy C., Li, Likun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2014
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4253400/ https://www.ncbi.nlm.nih.gov/pubmed/25301740

Ejemplares similares

Connecting androgen receptor signaling and the DNA damage response: Development of new therapies for advanced prostate cancer
por: Thompson, Timothy C., et al.
Publicado: (2017)

New immunotherapeutic paradigms for castration-resistant prostate cancer
por: Galluzzi, Lorenzo
Publicado: (2013)

New ideas in preventing castration-resistant prostate cancer
por: Tsai, Yuan-Chin, et al.
Publicado: (2017)

New insights for drug resistance in metastatic castration-resistant prostate cancer
por: Kushwaha, Prem Prakash, et al.
Publicado: (2022)

Combining enzalutamide with PARP inhibitors: Pharmaceutically induced BRCAness
por: Thompson, Timothy C., et al.
Publicado: (2017)

N-MYC regulation of DNA damage response in neuroendocrine prostate cancer: mechanistic insight and novel combination therapy approaches
por: Thompson, Timothy C., et al.
Publicado: (2018)

New classification may assist the development of targeted therapies for treatment-refractory castration-resistant prostate cancer
por: Lin, Ching-Yu, et al.
Publicado: (2020)

Androgen resistance in prostate cancer
por: Waxman, J, et al.
Publicado: (2008)

DNA damage response and prostate cancer: defects, regulation and therapeutic implications
por: Karanika, Styliani, et al.
Publicado: (2014)

Prognostic marker and target in prostate cancer
por: Lavorgna, Giovanni, et al.
Publicado: (2015)

Perilesional sampling: the new standard for imaging-targeted prostate biopsies?
por: Thomas, Christian
Publicado: (2023)

Targeting protein myristoylation for the treatment of prostate cancer
por: Sulejmani, Essilvo, et al.
Publicado: (2018)

Adaptive pathways and emerging strategies overcoming treatment resistance in castration resistant prostate cancer
por: Armstrong, Cameron M., et al.
Publicado: (2016)

GLIPR1-ΔTM synergizes with docetaxel in cell death and suppresses resistance to docetaxel in prostate cancer cells
por: Karanika, Styliani, et al.
Publicado: (2015)

Oligometastatic prostate cancer: is it worth targeting the tip of the iceberg?
por: Supiot, Stéphane, et al.
Publicado: (2019)

New prostate cancer grade group system correlates with prostate cancer death in addition to biochemical recurrence
por: Epstein, Jonathan I
Publicado: (2016)

Mismatch repair enzyme expression in primary and castrate resistant prostate cancer
por: Nghiem, Belinda, et al.
Publicado: (2016)

Prostate Cancer: From Molecular Imaging to Immunological and Target Therapies
por: Filippi, Luca, et al.
Publicado: (2023)

Advances in Radiotherapy for Prostate Cancer Treatment
por: Podder, Tarun, et al.
Publicado: (2016)

Genetic classifiers for prostate cancer: A new era on the horizon?
por: Hong, Sung Kyu
Publicado: (2015)

Prostate cancer and hypofractionation: really a new standard of care?
por: Carrie, Christian, et al.
Publicado: (2016)

What Is New in the Management of High-Risk Localized Prostate Cancer?
por: Wani, Mudassir, et al.
Publicado: (2023)

The earlier the better? Apalutamide for non-metastatic castration resistant prostate cancer
por: De Santis, Maria, et al.
Publicado: (2019)

Crosstalk between KIF15 and AR in castrate-resistant prostate cancers
por: Yang, Hanny, et al.
Publicado: (2022)

MicroRNAs in Prostate Cancer: Implications for Treatment Response and Therapeutic Targets
por: Hussein, Mohamed Ali, et al.
Publicado: (2023)

Targeting the Roots of Recurrence: New Strategies for Eliminating Therapy-Resistant Breast Cancer Stem Cells
por: Dahn, Margaret L., et al.
Publicado: (2020)

Targeting molecular resistance in castration-resistant prostate cancer
por: Chandrasekar, Thenappan, et al.
Publicado: (2015)

Metastasis-directed therapy: a new standard for oligorecurrent prostate cancer?
por: Zilli, Thomas, et al.
Publicado: (2018)

The promise of dual targeting Akt/mTOR signaling in lethal prostate cancer
por: Floc'h, Nicolas, et al.
Publicado: (2012)

New Insights into Diagnosis and Treatment of Renal Cell Carcinoma, Bladder Cancer, and Prostate Cancer
por: Chlosta, Piotr L., et al.
Publicado: (2017)

Prostate Cancer
por: Eggener, Scott
Publicado: (2011)

Targeting DNA repair pathways to overcome cancer drug resistance
por: van Waardenburg, Robert C.A.M., et al.
Publicado: (2021)

Novel anti-androgen receptor signaling agents: Understanding the mechanisms of resistance
por: Karanika, Styliani, et al.
Publicado: (2014)

New insights on the early prostate cancer diagnosis in a real-world setting
por: Lakshmanan, Vinoth-Kumar, et al.
Publicado: (2022)

Nonmetastatic castration-resistant prostate cancer: Novel agents to treat a lethal disease
por: Henriquez, Ivan, et al.
Publicado: (2021)

Prostate cancer and prostatic diseases is “Your” journal
por: De Nunzio, Cosimo
Publicado: (2022)

Long non-coding RNAs: new frontiers for advancing personalized cancer medicine in prostate cancer
por: Ghiam, Alireza Fotouhi, et al.
Publicado: (2017)

Aspirin and prostate cancer prevention
por: Vidal, Adriana C., et al.
Publicado: (2015)

Caveolin-1 regulates hormone resistance through lipid synthesis, creating novel therapeutic opportunities for castration-resistant prostate cancer
por: Karantanos, Theodoros, et al.
Publicado: (2016)

Hedgehog in prostate cancer explained
por: Buttyan, Ralph, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_4he53ioqfqhgrf182cifvn899r